Ciprandi Giorgio, Marseglia Gian Luigi
Casa di Cura Villa Montallegro.
University of Pavia and Policlinico San Matteo di Pavia.
Multidiscip Respir Med. 2024 Dec 12;19(1):986. doi: 10.5826/mrm.2024.986.
Pidotimod is a synthetic dipeptide that exerts immunomodulatory activity, modifying innate and adaptive immunity. Pidotimod firstly acts on Toll-like receptors, then on antigen-presenting cells and other immunocompetent cells. Pidotimod also affects immunoglobulin production and their switching. Evidence shows that pidotimod effectively and safely prevents respiratory infections, mainly in children with recurrent and frequent infectious episodes. In addition, pidotimod may be helpful as an add-on strategy in managing children with infections. Finally, there is evidence that pidotimod, thanks to its immunomodulatory activity and preventing respiratory infections (the main trigger for asthma exacerbation), may be beneficial in managing subjects with asthma and allergic diseases. The present review presents and discusses the most recent studies conducted in children with asthma, allergic rhinitis, recurrent respiratory infections and acute infections. Lastly, pidotimod is safe and well-tolerated in children.
匹多莫德是一种具有免疫调节活性的合成二肽，可调节固有免疫和适应性免疫。匹多莫德首先作用于Toll样受体，然后作用于抗原呈递细胞和其他免疫活性细胞。匹多莫德还会影响免疫球蛋白的产生及其类别转换。有证据表明，匹多莫德能有效且安全地预防呼吸道感染，主要针对反复频繁发生感染的儿童。此外，匹多莫德作为治疗感染儿童的辅助策略可能会有所帮助。最后，有证据表明，由于匹多莫德具有免疫调节活性并能预防呼吸道感染（哮喘发作的主要诱因），因此可能对哮喘和过敏性疾病患者有益。本综述介绍并讨论了针对哮喘、过敏性鼻炎、反复呼吸道感染和急性感染儿童开展的最新研究。最后，匹多莫德在儿童中安全且耐受性良好。
